検査と技術51巻9号

2023年09月発行

増大号 匠から学ぶ　血栓止血検査ガイド 3章　検査プロセス

フィブリノゲン（Fbg）

著者： 鈴木敦夫¹

所属機関： ¹名古屋大学医学部附属病院医療技術部臨床検査部門

ページ範囲：P.969 - P.973

はじめに

　フィブリノゲン（fibrinogen：Fbg）は，3つのポリペプチド（Aα鎖，Bβ鎖，γ鎖）から成るヘテロ3量体が重合してダイマーを形成した6量体〔（AαBβγ）₂〕で，分子量約340 kDaの糖タンパク質である．肝実質細胞で合成され，循環血漿中あるいは血小板α顆粒中に含まれる．血中半減期はおよそ3〜4日である．Fbgは極めて多様な機能をもつが，凝血学的には一次止血および二次止血の両者において極めて重要な働きを有する．特に，Fbgからフィブリンへの転化は二次止血（血液凝固反応）において最終段階を担う反応であり，生体の止血能を評価するうえでは重要なスクリーニング検査項目のうちの1つである．

参考文献

1）Mackie IJ, et al. Guidelines on fibrinogen assays. Br J Haematol. 2003; 121: 396-404.

2）Clauss A. [Rapid physiological coagulation method in determination of fibrinogen]（German）. Acta Haematol. 1957; 17: 237-246.

3）Molinaro RJ, et al. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology 2008; 109: 160-161.

4）Siegmund R, et al. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagul Fibrinolysis. 2008; 19: 288-293.

5）Dager WE, et al. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012; 46: 1627-1636.

6）Zhang L, et al. Influences of argatroban on five fibrinogen assays. Int J Lab Hematol. 2017; 39: 641-644.

7）Kanda GS, et al. Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran. Pathology 2021; 53: 623-627.

8）Jennings I, et al. Effect of direct thrombin inhibitors on laboratory measurement of fibrinogen: Potential for errors in clinical decision-making. Int J Lab Hematol. 2023.（online ahead of print）

9）Chitolie A, et al. Inaccuracy of the ‘derived’ fibrinogen measurement. Blood Coagul Fibrinolysis. 1994; 5: 955-957.

10）van den Besselaar AM, et al. Harmonization of fibrinogen assay results: study within the framework of the Dutch project ‘Calibration 2000’. Int J Lab Hematol. 2009; 31: 513-520.

11）Dorn-Beineke A, et al. Evaluation of the automated coagulation analyzer Sysmex CA-7000. Thromb Res. 2005; 116: 171-179.

12）Magnani B, et al. Degree of agreement in plasma fibrinogen among two functional and one immunonephelometric assays. Am J Clin Pathol. 1997; 107: 527-533.

13）永田和寛，他．ファクターオートフィブリノーゲンの基礎性能評価とフィブリノーゲン異常症例における測定値の検討．医学検査　2018；67：7-12．

14）鈴木敦夫，他．フィブリノゲン抗原量測定試薬　N-アッセイTIA FibのCS-5100用新規アプリケーション設定．日検血会誌．2017；18：54-60．

フィブリノーゲン」のCS-5100用新規アプリケーション設定．医学検査　2019；68：519-524．

16）Casini A, et al. Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost. 2018; 16: 1887-1890.

17）Krammer B, et al. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res. 1994; 76: 577-579.

18）Suzuki A, et al. Development and validation of a novel qualitative test for plasma fibrinogen utilizing clot waveform analysis. Sci Rep. 2022; 12: 434.

19）Dear A, et al. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain. Haematologica 2007; 92: e111-e117.

20）Arai S, et al. Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation. Int J Hematol. 2020; 112: 96-104.

21）Fibrinogen Studies Collaboration; Danesh J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005; 294: 1799-1809.

22）Suzuki A, et al. Clot waveform analysis in Clauss fibrinogen assay contributes to classification of fibrinogen disorders. Thromb Res. 2019; 174: 98-103.

23）Arai S, et al. Automated screening procedure for the phenotypes of congenital fibrinogen disorders using novel parameters, |min1|c and Ac/|min1|c, obtained from clot waveform analysis using the Clauss method. Clin Chim Acta. 2021; 521: 170-176.